Great work @sachinjshah. It took many years for the prostate cancer community to take an analogous approach to treatment stratification in older men (though work remains). hope same continues to happen in AF (esp for my frail patients with both prostate cancer and AF!!) @myCARG.

Our thoughts on "rehabbed to death" in oncology. Recommend 1) prognostic and functional assessment, 2) clear criteria for rehab progress, and 3) early identification of those unlikely to benefit from rehab.

RT @cdumonti: Insightful commentary by @dlage et al. Need to follow function when considering appropriateness for cancer Tx, as well as re….

RT @lpetrillz: This is huge. Their NEJM 2010 pub set the standard, and now Temel & Greer have taken the next STEP to show us how palliative….

RT @RyanNipp: Comparative effectiveness trial of early #palliative care delivered via telehealth versus in person among patients with advan….

RT @KellyIrwin_MD: APOS health equity scholar Angela Mendez sharing strategies to adapt supportive care interventions for minoritized men w….

RT @TiansterZhang: One more top 5 #bladdercancer -- which may be most anticipated GU track @myESMO #ESMO23 -- EV-302 looks to be game chan….

Proud to highlight prostate cancer health disparities and the need for better screening and outreach alongside amazing colleagues @MGHCancerCenter @RickLee6 @BrendaLormil @BeverlyMoy #EdwinChoy Also, the Boston Rhythm Riders Line Dancers have some impressive moves, so fun!!.

25% of days from diagnosis to death in metastatic GI cancer are spent in an inpt or outpt facility. Drives home the need for home-based oncology care delivery models as a win for patient experience and costs @JCOOP_ASCO @guptaarjun90 @GRocqueMD @RyanNipp.

Thoughtful discussion of the next frontier and challenges in value-based oncology: I think the transition from FFS to capitated/global payments will be more challenging than most anticipate, but ultimately beneficial for patients & care deliver innovation.

What’s the hardest part of being an oncologist? Giving difficult news to patients? Keeping up with rapid clinical and scientific advances? No, it’s “Having so many rules and regulations”

Interesting work. We effectively tell patients to figure it out on their own after hospital discharge. I wonder how that will go for seriously ill patients, those with poor health literacy, socioeconomic status, social supports, etc?? Thanks for sharing @RyanNipp.

So glad you’re keeping the tradition alive! Visit dinners are the best, so important to connect on a human/social level after spending so much time caring for complex/sick patients. @MGHCancerCenter @RickLee6.

RT @sophia_kamran: Successful 💪🏽session with all-star ⭐️line up of speakers!! .Rare tumors (penile and seminoma) but lots of great data pre….

Great point! Agreed that anemia and its impact on health care utilization and QOL needs to be studied much more carefully.

A big theme of PROPEL and PARPi in general is how to manage anemia and other toxicities. Would love to see analyses and measures focused on the impact of anemia/cytopenias beyond the FACT-P, and also transfusions, workup and health care utilization due to these AE’s #ASCOGU23.

Really helpful subgroup data from ARASENS on how patients with high vs low risk/volume disease benefit from triplet therapy. Builds on last year’s impressive initial results. Will help guide selection of therapy for pts with mHSPC. @JCO_ASCO #GU23 @ASCO

So far, trial data hasn't matched what I'm hearing to be the clinical experiences/needs "on the ground," i.e. more toxicity and difficulty staying on treatment than expected based on trial data. Just anecdotal but hoping to study this.

Great discussion on PARP inhibitors in prostate cancer right now. I think that closer study of side effects, quality of life & health care utilization in real-world populations will be essential to understand how to implement this interesting data in clinical practice. #ASCOGU23.